Using nature's blueprint to expand catalysis with Earth-abundant metals
BACKGROUND Catalysis has had a transformative impact on society, playing a crucial role
in the production of modern materials, medicines, fuels, and chemicals. Precious metals …
in the production of modern materials, medicines, fuels, and chemicals. Precious metals …
[HTML][HTML] Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
…, X Ding, H Mo, JC Yang… - … England Journal of …, 2014 - Mass Medical Soc
Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …
[HTML][HTML] Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
…, Y Zhu, H Dvory-Sobol, JC Yang… - … England Journal of …, 2014 - Mass Medical Soc
Background Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients
who have not had a sustained virologic response to prior interferon-based therapy represents …
who have not had a sustained virologic response to prior interferon-based therapy represents …
Viral calciomics: interplays between Ca2+ and virus
Y Zhou, TK Frey, JJ Yang - Cell calcium, 2009 - Elsevier
Ca 2+ is one of the most universal and versatile signaling molecules and is involved in
almost every aspect of cellular processes. Viruses are adept at utilizing the universal Ca 2+ …
almost every aspect of cellular processes. Viruses are adept at utilizing the universal Ca 2+ …
[PDF][PDF] Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase
X Gao, H Wang, JJ Yang, X Liu, ZR Liu - Molecular cell, 2012 - cell.com
Pyruvate kinase isoform M2 (PKM2) is a glycolysis enzyme catalyzing conversion of
phosphoenolpyruvate (PEP) to pyruvate by transferring a phosphate from PEP to ADP. We report …
phosphoenolpyruvate (PEP) to pyruvate by transferring a phosphate from PEP to ADP. We report …
[HTML][HTML] Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1
…, J Santana-Bagur, LM Stamm, JC Yang… - … England Journal of …, 2015 - Mass Medical Soc
Background Effective treatment for hepatitis C virus (HCV) in patients coinfected with human
immunodeficiency virus type 1 (HIV-1) remains an unmet medical need. Methods We …
immunodeficiency virus type 1 (HIV-1) remains an unmet medical need. Methods We …
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing
LM Lim, N Ly, D Anderson, JC Yang… - … : The Journal of …, 2010 - Wiley Online Library
Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of
gram‐negative infections. After several years of clinical use, its popularity diminished because …
gram‐negative infections. After several years of clinical use, its popularity diminished because …
[HTML][HTML] An adversarial training framework for mitigating algorithmic biases in clinical machine learning
Abstract Machine learning is becoming increasingly prominent in healthcare. Although its
benefits are clear, growing attention is being given to how these tools may exacerbate existing …
benefits are clear, growing attention is being given to how these tools may exacerbate existing …
The etr1‐2 mutation in Arabidopsis thaliana affects the abscisic acid, auxin, cytokinin and gibberellin metabolic pathways during maintenance of seed dormancy …
…, AJ Cutler, SR Abrams, SJ Ambrose, J Yang… - The Plant …, 2005 - Wiley Online Library
In Arabidopsis thaliana, the etr1‐2 mutation confers dominant ethylene insensitivity and
results in a greater proportion of mature seeds that exhibit dormancy compared with mature …
results in a greater proportion of mature seeds that exhibit dormancy compared with mature …
Rational design of protein-based MRI contrast agents
JJ Yang, J Yang, L Wei, O Zurkiya… - Journal of the …, 2008 - ACS Publications
We describe the rational design of a novel class of magnetic resonance imaging (MRI) contrast
agents with engineered proteins (CAi.CD2, i = 1, 2,..., 9) chelated with gadolinium. The …
agents with engineered proteins (CAi.CD2, i = 1, 2,..., 9) chelated with gadolinium. The …